Q1 FY27 results: standalone PAT up 54%, revenue rises 15%
MEDICAMEQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.5 pts less than Nifty Microcap 250 and 8.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Medicamen Biotech Q1 FY27 standalone total revenue rose 14.9% to Rs 4,471.43 lakh and net profit jumped about 54% to Rs 252.69 lakh, with EPS at Rs 1.86 versus Rs 1.21. Consolidated revenue rose 12% to Rs 4,875.85 lakh and consolidated PAT grew about 15% to Rs 184.60 lakh. Board approved a Rs 1 per share final dividend and the 33rd AGM for September 26, 2026. The company paid about Rs 1.1 lakh in fines each to BSE and NSE for an earlier NRC composition non-compliance. Auditors issued an unmodified limited review report.
Profit jump on revenue growth and clean audit view are positive; proposed dividend is supportive. Past NRC compliance lapse is a minor red flag.